Skip to main content
Delfa

← All trials/NCT07728383

RecruitingPhase 4

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

40

Study population

Obesity / overweight

Eligibility highlights

•BMI 30-45

Primary endpoint

-

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07728383
Org study IDGT-G-C-102

Timeline

Milestones

Study start2026-06-17actual
Study first posted2026-07-27actual
Last update posted2026-07-27actual
Primary completion2027-05estimated (month precision)
Study completion2027-05estimated (month precision)

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Body Mass Index 30 to 45

Exclusion criteria

•Type 2 Diabetes Mellitus
•Multiple Endocrine Neoplasia Type 2
•Medullary thyroid cancer

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.